Imipenem is a member of a new class of highly potent I8-lactam antibiotics, carbapenems, with a very broad antibacterial spectrum. This study was undertaken to determine tentative interpretive criteria for in vitro susceptibility testing with 10-,ug imipenem disks. A careful examination of the zone diameters and the corresponding MICs for 489 clinical isolates by regression-line analysis and the error rate-bounded classification scheme suggested the following guidelines: .16 mm with an MIC correlate of s4 ,ig/ml for susceptible, 14 to 15 mm (8 ,ug/ml) for moderately susceptible, and <13 mm (.16 ,ug/ml) for resistant. Lack of cross-resistance between imipenem and broad-spectrum cephalosporins such as cefotaxime and ceftazidime argues against their use as class disks to predict in vitro susceptibility of bacterial species to carbapenems.
Imipenem (N-formimidoyl thienamycin) is a member of a new class of potent ,-lactam compounds, carbapenems, with an unusually broad antibacterial spectrum (2, 3, 6, 7) . In addition to the usual bacterial species inhibited by the acylamino penicillins and the broad-spectrum cephalosporins, imipenem has substantial in vitro activity against Acinetobacter species, pseudomonads except Pseudomonas cepacia and Pseudomonas maltophilia, staphylococci including methicillin-resistant strains of Staphylococcus aureus, enterococci except Streptococcus faecium, and virtually all commonly isolated and clinically significant anaerobic bacterial species.
The study herein reported was undertaken to define appropriate susceptibility criteria for interpreting the results of agar diffusion tests with 10-,ug imipenem disks as a guide to therapy.
(This work was presented in part at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 8 itor of dehydropeptidase-1, in a 1 to 1 ratio (4, 12). Inhibition of this mammalian renal P-lactamase located at the brush border of the proximal tubular cells protects imipenem from extensive enzymatic degradation. Cilastatin is devoid of any antibacterial activity of its own and does not interfere with the intrinsic activity of imipenem. Available human pharmacokinetic data show that imipenem levels in plasma of >32 and >64 ,ug/ml can be achieved after intravenous administration of single doses of imipenem and cilastatin of 500 and 500 mg and 1,000 and 1,000 mg, respectively (2, 12) . With a plasma half-life of approximately 1 h, mean levels in serum of 3.5 ,ug/ml (500-mg dose) and 7 ,ug/ml (1,000-mg dose) can be detected 3 h after administration (Fig. 1.) .
There is no uniform agreement concerning the minimal ratio between levels in blood and MICs or on how long the level in plasma should exceed the MIC to ensure therapeutic efficacy. However, it is generally believed that with the normally recommended dose, the MIC breakpoint of an antibacterial agent should exceed or equal the expected mean level in serum for at least half the dosage interval (5, 11) . Based on these considerations and on a proposed four-or three-times-daily dosage regimen for imipenem, 4 and 16 ,ug/ml appear to be the most logical choices for susceptible and resistant MIC breakpoints, respectively.
Both the computer-assisted scattergram of MICs versus Of the 489 clinical isolates included in the present study, 95 were resistant to one or more of the three antimicrobial agents tested. Thirteen of these, or 13.7%, were resistant to imipenem, 67 (70.5%) were resistant to cefotaxime, and 70 (73.7%) were resistant to ceftazidime. On the basis of the MIC90 results, cross-resistance between all three antibiotics is suggested only against P. maltophilia. All of the test isolates resistant to imipenem were also resistant to cefotaxime and ceftazidime. However, 80.6 and 81.4% of the isolates resistant to cefotaxime and ceftazidime, respectively, were still susceptible to imipenem. Imipenem is unique among all P-lactam antibiotics in displaying substantial in vitro activities against S. faecalis, methicillin-resistant S. aureus, and Acinetobacter calcoaceticus (6, 13) . These observations suggest that the 10-,ug imipenem disk should be tested separately and that MICs or disk criteria applicable to ceftazidime, cefotaxime, and related compounds cannot be used to predict in vitro bacterial susceptibility to imipenem.
Obviously, the interpretive criteria herein proposed for in vitro susceptibility testing with the 10-,ug imipenem disks and which, to a great degree, confirm those proposed previously (1), are only tentative. They are meant for use as a guide to therapy during clinical trials and, therefore, are subject to reevaluation and modification depending on how well they predict bacteriologic eradication and clinical efficacy.
